Irinotecan in esophageal cancer.
Oncology (Williston Park)
; 14(12 Suppl 14): 26-30, 2000 Dec.
Article
in En
| MEDLINE
| ID: mdl-11200145
ABSTRACT
Irinotecan (Camptosar) has shown activity in several solid tumor malignancies, including gastric and pancreatic cancer. In vitro studies suggest antitumor activity in esophageal cancer cell lines. Sequence-dependent synergy has been demonstrated in vitro between irinotecan and cisplatin. A phase I trial conducted at Memorial Sloan-Kettering Cancer Center (MSKCC) has demonstrated the safety and tolerability of cisplatin plus irinotecan. A phase II study of this combination in patients with previously untreated, advanced esophageal cancer, also at MSKCC, has demonstrated promising results. Current trials at MSKCC are attempting to combine this regimen with either paclitaxel (Taxol), fluorouracil (5-FU), or radiation therapy.
Search on Google
Database:
MEDLINE
Main subject:
Camptothecin
/
Esophageal Neoplasms
/
Enzyme Inhibitors
/
Topoisomerase I Inhibitors
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2000
Type:
Article